MedTrace Logo

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

NCT01266369 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-12-10

No results posted yet for this study

Summary

The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of patients with mastocytosis with handicap and bearing activating point mutations in the phosphotransferase domain of c-Kit such as the main mutation Asp-816-Val (D816V).

Conditions

  • Mastocytosis

Interventions

DRUG

masitinib

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Olivier Lortholary, MD, PhD · Necker Hospital, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-11-30
Completion
2010-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266369 on ClinicalTrials.gov